山东大学耳鼻喉眼学报 ›› 2017, Vol. 31 ›› Issue (1): 123-126.doi: 10.6040/j.issn.1673-3770.0.2016.454

• 无栏目 • 上一篇    下一篇

视网膜静脉阻塞的发病机制及黄斑水肿的抗-VEGF治疗

韩克阳1,王淑雅2,焦芮1,于贝贝3, 赵博军4   

  1. 1.山东中医药大学第二临床医学院, 山东 济南 250001;
    2.山东中医药大学附属眼科医院, 山东 济南 250003;
    3.山东中医药大学第一临床医学院, 山东 济南 250014;
    4.山东大学附属省立医院眼科中心, 山东 济南 250021
  • 收稿日期:2016-11-01 出版日期:2017-02-16 发布日期:2017-02-16
  • 通讯作者: 赵博军. E-mail:zhaobojun@hotmail.com
  • 基金资助:
    山东省自然科学基金(ZR2015HM026)

The pathogenesis of RVO and anti-VEGF treatment for its macular edema.

  1. 1. The Second School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250001, Shandong, China;2. The Ophthalmic Hospital Affiliated to Shandong University of Traditional Chinese Medicine, Jinan 250003, Shandong, China;3. The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong, China;4. Ophthalmic Center Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Received:2016-11-01 Online:2017-02-16 Published:2017-02-16

PDF (PC)

1175

被引次数

7

摘要： 视网膜静脉阻塞(RVO)是临床上常见的视网膜血管疾病,其继发的黄斑水肿则是导致视力受损的重要原因,近年来玻璃体内注射抗VEGF药物在消除黄斑水肿及提高患者视力上取得了明显的疗效。主要就视网膜静脉阻塞的流行病学、病理机制以及黄斑水肿的治疗现状做一综述。

关键词: 视网膜静脉阻塞, 黄斑水肿, 抗-VEGF

Abstract: RVO is a common retinal vascular disease. Macular edema is one of major cause to induce visual damage. With the application of anti-VEGF drug in clinic, macular edema can be reduced and vision is improved. The essay mainly summarized the epidemiologies and mechanisms of retinal vein occlusion and the treatment of macular edema with anti-VEGF reagents.

Key words: Macular edema, Retinal vein occlusion, Anti-VEGF

中图分类号: 

  • R774
[1] 董宁. 视网膜静脉阻塞与血浆同型半胱氨酸、维生素B12和叶酸水平以及C677T MTHFR基因多态性的相关研究[D].天津:天津医科大学,2015.
[2] Dacheva I, Ullmer C, Ceglowska K, et al. Lysophosphatidic acids and autotaxin inretinal vein occlusion[J]. Retina, 2016, 36(12):2311-2318.
[3] Kuhli-Hattenbach C, Hellstern P, Miesbach W, et al. Prevalence of elevated lipoprotein(a)levels in patients <60 years of age with retinal vein occlusion[J]. Klin Monbl Augenheilkd, 2016.
[4] Stanca HT, Manea G. Physiopathology of macular edema in central vein Occlusion[J]. Oftalmologia, 2012, 56(2):15-20.
[5] Ojima T, Takagi H, Suzuma K, et al. EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and supper-sses retinal neovascularization and blood-retinal barrier breakdown[J]. Am J Pathol, 2006, 168(1):331-339.
[6] Campochiaro PA, Aiello LP, Rosenfeld PJ. Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside[J]. Ophthalmology, 2016, 123(10):S78-S88.
[7] Glanville J, Patterson J, McCool R, et al. Efficacy and safety of widely used treatments for macular oeddema secondary to retinal vein occlusion: a systematic review[J]. BMC Ophthalmol, 2014, 14(7):1-15.
[8] Campochiaro PA, Bhisitkul RB, Shapiro H, et al. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion[J]. Ophthalmology, 2013, 120(4):795- 802.
[9] 孟晓丽,冯俊. 视网膜分支静脉阻塞黄斑水肿的研究概况[J].中国中医眼科杂志,2014,24(1):66-69. MENG Xiaoli, FENG Jun. Research survey on macular edema of branch retinal vein occlusion[J]. Chin J Chin Ophthalmol, 2014, 24(1):66-69.
[10] Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion:an evidence-based systematic review[J]. Ophthalmology, 2010, 117(6):1094-1101.
[11] McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion:an evidence-based systematic review[J]. Ophthalmology, 2010, 117(6):1113-1123.
[12] 张璐,赵博军.视网膜静脉阻塞引起黄斑水肿的药物治疗进展[J]. 国际眼科杂志,2013,13(11):2227-2230. ZHANG Lu, ZHAO Bojun. Advance in pharmaco-therapy of macular edema in retinal vein occlusion[J]. Int Eye Sci, 2013, 13(11):2227-2230.
[13] 刘卫. 视网膜静脉阻塞继发黄斑水肿的治疗进展[J]. 中国眼耳鼻喉科杂志,2015,15(4):236-239.
[14] 黄厚斌,张卯年. 抗VEGF药物治疗视网膜静脉阻塞黄斑水肿的疗效及安全性评价[J]. 眼科新进展,2013,33(1):1-4. HUANG Houbin, ZHANG Maonian. Curative effects and safety evaluation of unti-VEGF drugs of macular edema induced by retinal vein occlusion[J]. Recent Advan Ophthalmol, 2013, 33(1):1-4.
[15] Zhang S, An N, Ha W, et al. Factors correlated with the resolution of macular oedema after one dose injection of intravitreal triamcinolone acetonide treatment in branch retinal vein occlusion[J]. J Int Med Res, 2016, 44(3):685-697.
[16] Tomiyasu T, Hirano Y, Yoshida M, et al. Microaneurysms cause refractory macular edema in branch retinal vein occlusion[J]. Sci Rep, 2016(6):29445.
[17] Sellam A, Glacet-Bernard A, Coscas F, et al. Qualitative and quantitative follow-up using optical coherence tomography angiography of retinal vein occlusion treated with anti-vegf: optical coherence tomography angiography follow-up of retinal vein occlusion[J]. Retina, 2016.
[18] Fujihara-Mino A, Mitamura Y, Inomoto N, et al. Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion[J]. Clin Ophthalmol, 2016(10):1305-1313.
[19] Casselholmde Salles M, Kvanta A, Amrén U, et al. Optical coherence tomography angiography in central retinal vein occlusion: correlation between the foveal avascular zone and visual acuity[J]. Invest Ophthalmol Vis Sci, 2016, 57(9):242-246.
[20] Balaratnasingam C, Inoue M, Ahn S, et al. Visual acuity is correlated with the area of the foveal avascular zone in diabetic retinopathy and retinal vein occlusion[J]. Ophthalmology, 2016, 123(11):2352-2367.
[1] 朱明琼,李征,刘茹,田涛,彭婧利,吕倩怡,谭华霞. 基于OCT/OCTA的AI筛查系统在抗VEGF治疗糖尿病性黄斑水肿患者效果评价中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 68-73.
[2] 孙庆祝,沈健,陈星,吴雁冰,曾论. 代谢指标在预测糖尿病性黄斑水肿患者雷珠单抗疗效中的作用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 74-81.
[3] 朱云龙,王平,高萌. 误诊为中浆及视网膜炎的后巩膜炎1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 99-105.
[4] 丁术梁,王超凡,刘建亮. 眼内液检测指导精准治疗急性视网膜坏死1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 114-117.
[5] 沈嘉琪,李潇飒,毕燕龙,张敬法. 人工智能在DME筛查、诊断和预后中的应用[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 153-159.
[6] 鲍莹,刘志高,姜鹏飞,崔文轩,郑晓霞,杨梦瑶,司明威,王玉,王红. 康柏西普治疗糖尿病合并CRVO-ME高反射点的临床观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 55-60.
[7] 常威威,焦万珍,崔艳艳,赵杰,刘兆强,赵博军. 糖尿病性黄斑缺血的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 130-136.
[8] 周静琳,李金香,曾琦. 577 nm阈值下微脉冲激光联合抗VEGF药物治疗难治性糖尿病性黄斑水肿的疗效观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 18-25.
[9] 何静,雷春燕,张美霞. 糖化血红蛋白变异指数与糖尿病视网膜病变严重程度的相关性研究[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 34-40.
[10] 刘天蔚,赵博军. 年轻人群视网膜静脉阻塞研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 128-137.
[11] 唐慧新,李景景,邹红. 阈值下微脉冲激光光凝作用机制及临床应用[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 143-148.
[12] 顾冉冉,李凤娇,焦万珍,崔艳艳,赵博军. 卵磷脂络和碘胶囊辅助治疗视网膜静脉阻塞的临床疗效研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 46-50.
[13] 韩克阳,于贝贝,赵博军. 短期视网膜静脉阻塞抗VEGF治疗后黄斑区形态结构分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(5): 129-131.
[14] 刘建波,张环. 超声乳化联合玻璃体腔药物注射治疗白内障合并糖尿病性黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 99-104.
[15] 梁倩倩,杨庭骅,赵博军. 光学相干层析血管扫描在视网膜静脉阻塞中的应用[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 139-142.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发